Bald geht los !!!!

|Birgit Stattin-Norinder|11,139   |46,935       |0.007%                        |
+-----------------------+---------+-------------+-
|Michael Lewis          |42,148   |339,593      |0.05%                         |
+-----------------------+---------+-------------+-


Application will be made to the London Stock Exchange and the UK Listing
Authority for the admission of the new ordinary shares of 1p each. The total
number of ordinary shares in the Company in issue and admitted to the Official
List following the above allotments will be 629,256,502.


www.investegate.co.uk/Article.aspx?id=20100505103000H2023

PPM1D Inhibitor Programme PPM1D is aberrantly amplified in a range of cancers. PPM1D Inhibitor Programm PPM1D wird aberrant Krebserkrankungen verstärkt im Bereich von. Activation results in negative regulation of p53 function and other tumour suppressor pathways. Additional functions include the regulation of the base excision pathways of DNA repair. Die Aktivierung führt zu negativen Regulation von p53-Funktion und anderen Tumor-Suppressor-Bahnen. Zusätzliche Funktionen umfassen die Regulierung der Basis Exzision Wege der DNA-Reparatur. Programme is at lead optimisation Programm richtet sich an die Lead-Optimierung

Dendritic Cell Autoimmune Modulators (DCAM) A novel class of oral agents that target specific populations of dendritic cells to modulate the immune response Dendritische Zellen Autoimmun-Modulatoren (DCAM) Eine neue Klasse von oralen Antidiabetika, dass Zellen auf spezifische Populationen von dendritischen zu modulieren die Immunantwort

In-licensing In-Lizenzierung

Antisoma seeks opportunities to in-license novel, targeted cancer drug candidates. Antisoma Möglichkeiten sucht, um in-Lizenz neuartige, zielgerichtete Krebsmedikament Kandidaten. The Company maintains ongoing research collaborations with many of the institutions where its drugs were first developed. Die Gesellschaft unterhält laufende Forschungskooperationen mit vielen Einrichtungen, in denen ihre Medikamente entwickelt wurden zunächst.

We welcome contact from research institutions and biotech/biopharmaceutical companies that have targeted cancer products, in late preclinical stage development. Wir begrüßen Kontakt aus Forschungseinrichtungen und Biotech / biopharmazeutisches Unternehmen, die Produkte gezielt Krebs haben, im späten präklinischen Stadium der Entwicklung. We are also interested in discussing earlier, preclinical stage collaborations. Wir sind auch Kooperationen interessiert diskutieren früheren präklinischen Stadium.

Antisoma is currently seeking the following development-stage drug candidates in cancer: Antisoma sucht derzeit die folgende Entwicklung Entwicklungsstadium befindliche Wirkstoffkandidaten in der Krebstherapie:

   * Late pre-clinical (with in vivo proof-of-principle data) Späten präklinischen Phase (mit In-vivo-proof-of-Principle-Daten)

www.antisoma.com/asm/partnering/

Products

   * Pipeline
   * AS1413 (amonafide L-malate, formerly Xanafide®)
   * AS1411
   * ASA404

Antisoma focuses its activities on treatments for cancer, an area of significant unmet medical need.

Antisoma has a diverse portfolio of products in development. Our products target tumours by several different mechanisms and are intended for the treatment of a range of cancers.
AS1413 (amonafide L-malate)


A DNA intercalator in phase III  in secondary AML

More on AS1413

AS1411


A DNA aptamer in phase II in AML

More on AS1411


ASA404 (DMXAA)

www.antisoma.com/asm/products/